基石药业(02616.HK):已向欧洲药品局提交舒格利单抗新适应症申请

阿斯达克财经
Mar 24, 2025

基石药业-B(02616.HK) 公布,已向欧洲药品管理局提交舒格利单抗的新适应症申请,用于治疗同步或序贯放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌(NSCLC)患者。若顺利获批,舒格利单抗将填补III期非小细胞肺癌这一疾病领域的关键需求,成为欧洲第二款治疗该适应症的PD-(L)1抗体。同时,舒格利单抗在III期和IV期非小细胞肺癌中的双重应用,将进一步巩固其作为肺癌核心免疫疗法的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10